Patents by Inventor Hanns-Martin Schmidt

Hanns-Martin Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230400417
    Abstract: The invention concerns, amongst others, a device (1) for specific illumination of at least one biological sample, the device (1) comprising a multitude of cavities (2), each cavity (2) representing an internal space (3) being capable of holding the biological sample. The internal spaces (3) are each partially surrounded by a wall element (4) comprising windows (5) for observing and/or illuminating the internal spaces (3). In order to protect the internal spaces (3) from the ingress of light, the wall element (4) comprises a light-proof material. Each window (5) comprises at least one switchable element (8) being of switchable color and/or light transmittance. By the switchable elements (8), light exposure of the biological sample in the internal space (3) of each cavity (2) can be controlled so that unintended light exposure can be effectively avoided when illumination of the sample does not occur and/or the device (1) is stored or transported.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 14, 2023
    Applicant: Ningaloo Biosystems GmbH
    Inventors: Herbert Mueller-Hartmann, Hanns-Martin SCHMIDT
  • Patent number: 11193156
    Abstract: The present invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins, cell lines that can be used in said methods, respective recombinant glycoproteins, and methods for expressing the same in said cell lines.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: December 7, 2021
    Assignee: Cevec Pharmaceutical GmbH
    Inventors: Hanns-Martin Schmidt, Markus Ribbert, Gudrun Schiedner, Silke Wissing, Jens Wölfel
  • Publication number: 20200032311
    Abstract: The present invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins, cell lines that can be used in said methods, respective recombinant glycoproteins, and methods for expressing the same in said cell lines.
    Type: Application
    Filed: March 15, 2018
    Publication date: January 30, 2020
    Applicant: Cevec Pharmaceutical GmbH
    Inventors: Hanns-Martin Schmidt, Markus Ribbert, Gudrun Schiedner, Silke Wissing, Jens Wölfel
  • Patent number: 7999073
    Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: August 16, 2011
    Assignee: Lonza Cologne GmbH
    Inventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tatjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Tamara Grabek, Andrea Mueller-Hartmann
  • Publication number: 20080220527
    Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.
    Type: Application
    Filed: November 21, 2007
    Publication date: September 11, 2008
    Applicant: AMAXA AG
    Inventors: Hanns-Martin SCHMIDT, Ludger ALTROGGE, Dietmar LENZ, Gudula RIEMEN, Helmut BROSTERHUS, Elke LORBACH, Juliana HELFRICH, Katharina HEIN, Marion GREMSE, Tatjana MALES, Rainer CHRISTINE, Gregor SIEBENKOTTEN, Bodo ORTMANN, Tamara GRABECK, Andrea MULLER-HARTMANN
  • Patent number: 7320859
    Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: January 22, 2008
    Assignee: Amaxa AG
    Inventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tatjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Tamara Turbanski, Andreas Klaes
  • Publication number: 20040137622
    Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.
    Type: Application
    Filed: August 13, 2003
    Publication date: July 15, 2004
    Inventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tarjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Andrea Klacs